<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704921</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-314-2104</org_study_id>
    <nct_id>NCT04704921</nct_id>
  </id_info>
  <brief_title>Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD</brief_title>
  <acronym>ATMOSPHERE</acronym>
  <official_title>A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular&#xD;
      (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision&#xD;
      due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of&#xD;
      vision loss in the United States, Europe and Japan, with up to 2 million people living with&#xD;
      wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed&#xD;
      the landscape for treatment of wet AMD, becoming the standard of care due to their ability to&#xD;
      prevent progression of vision loss in the majority of patients. These therapies, however,&#xD;
      require life-long intraocular injections, typically repeated every four to 12 weeks in&#xD;
      frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a&#xD;
      decline in vision with reduced frequency of treatment over time. RGX-314 is being developed&#xD;
      as a potential one-time treatment for wet AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, partially masked, controlled, Phase 2b/3 clinical study will evaluate the&#xD;
      efficacy and safety of RGX-314 gene therapy in participants with nAMD. The study will&#xD;
      evaluate 2 dose levels of RGX-314 relative to an active comparator. The primary endpoint of&#xD;
      this study is mean change in best-corrected visual acuity (BCVA) of RGX-314 relative to&#xD;
      ranibizumab. Approximately 300 participants who meet the inclusion/exclusion criteria, will&#xD;
      be enrolled into one of 3 arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 RGX-314 treatment arms, 1 control arm (ranibizumab)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The administration of RGX-314 requires an outpatient surgical procedure performed in an operating room, while the active control, ranibizumab, is administered via intravitreal injection in an office setting. This study will be partially masked which will include masking of key study assessors and study drug dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>At Week 54</time_frame>
    <description>BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidences of ocular and overall adverse events (AEs)</measure>
    <time_frame>Through Week 98</time_frame>
    <description>Evaluate the safety and tolerability of RGX-314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>At Week 98 (RGX-314 randomized participants only)</time_frame>
    <description>BCVA measured by ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Central Retinal Thickness (CRT) and Center Point Thickness (CPT) as measured by Spectral Domain Optical Coherence Tomography (SD-OCT)</measure>
    <time_frame>At Week 54 and Week 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in supplemental anti VEGF injection annualized rate compared with the prior 52 weeks preceding the first ranibizumab injection received as part of the Active Run-in Period (RGX 314 randomized participants)</measure>
    <time_frame>Through Week 54 and Week 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean supplemental anti-VEGF injection annualized rate in the RGX-314 arms</measure>
    <time_frame>Through Week 54 and Week 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous RGX-314 target protein (TP) concentrations</measure>
    <time_frame>At Week 14, Week 26, Week 38, Week 54, and Week 98</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>AMD</condition>
  <condition>nAMD</condition>
  <condition>Wet Age-related Macular Degeneration</condition>
  <condition>wAMD</condition>
  <condition>Wet AMD</condition>
  <condition>CNV</condition>
  <arm_group>
    <arm_group_label>RGX-314 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 1 administered via subretinal delivery one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 2 administered via subretinal delivery one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab administered via intravitreal injection approximately every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RGX-314</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)</description>
    <arm_group_label>RGX-314 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RGX-314</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)</description>
    <arm_group_label>RGX-314 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ranibizumab (LUCENTIS®)</intervention_name>
    <description>0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Ranibizumab (anti-VEGF agent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 50 years and ≤ 89 years&#xD;
&#xD;
          2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye&#xD;
&#xD;
          3. Diagnosis of subfoveal CNV secondary to AMD in the study eye previously treated with&#xD;
             anti-VEGF&#xD;
&#xD;
          4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.&#xD;
&#xD;
          5. Willing and able to provide written, signed informed consent for this study&#xD;
&#xD;
          6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at&#xD;
             study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CNV or macular edema in the study eye secondary to any causes other than AMD&#xD;
&#xD;
          2. Subfoveal fibrosis or atrophy in the study eye&#xD;
&#xD;
          3. Any condition in the investigator's opinion that could limit VA improvement in the&#xD;
             study eye&#xD;
&#xD;
          4. Active or history of retinal detachment in the study eye&#xD;
&#xD;
          5. Uncontrolled glaucoma in the study eye&#xD;
&#xD;
          6. History of intraocular surgery in the study eye within 12 weeks prior to Screening&#xD;
             Visit 1&#xD;
&#xD;
          7. History of intravitreal therapy in the study eye, such as intravitreal steroid&#xD;
             injection or investigational product, other than anti-VEGF therapy, in the 6 months&#xD;
             prior to Screening Visit 1.&#xD;
&#xD;
          8. Prior treatment with gene therapy.&#xD;
&#xD;
          9. Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack&#xD;
             within the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-860-0117</phone>
    <email>patientadvocacy@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Location</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Location</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Durango Location</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gainesville Location</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta Location</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aiea Location</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indianapolis Location</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Albany Location</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baltimore Location</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Location</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Oak Location</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minneapolis Location</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Location</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reno Location</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albuquerque Location</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Location</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Location</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philadelphia Location</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rapid City Location</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germantown Location</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abilene Location</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Location</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin 2 Location</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dallas Location</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Location</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Beach Location</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Madison Location</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Wet Macular Degeneration</keyword>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Angiogenesis Inhibitors</keyword>
  <keyword>Angiogenesis Modulating Agents</keyword>
  <keyword>Growth Substances</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Growth Inhibitors</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Anti-vascular endothelial grown factory therapy</keyword>
  <keyword>Anti-VEGF therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

